Meeting NewsVideo

VIDEO: Speaker offers updates in cutaneous squamous cell carcinoma

NEW YORK — Axel Hauschild, MD, professor of dermatology and head of dermato-oncology at University Hospital in Kiel, Germany, provided an update on treatment of cutaneous squamous cell carcinoma during HemOnc Today Melanoma and Cutaneous Malignancies.

“Cutaneous squamous cell carcinoma is the second most frequent nonmelanoma skin cancer,” Hauschild said. “Ninety percent of these cases have an excellent prognosis because they carry good prognostic factors.”

The treatment of choice among physicians tends to be surgical excision. However, alternatives for inoperable and metastatic disease include radiotherapy, chemotherapy and EGFR inhibitors.

Reference:

Hauschild A. Update on advanced squamous cell carcinomas. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; March 24-25, 2017; New York.

Disclosure: Hauschild reports consultant or speakers roles with Amgen, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme, Novartis, OncoSec, Philogen, Peirre Fabre, Provectus, Regeneron and Roche.

NEW YORK — Axel Hauschild, MD, professor of dermatology and head of dermato-oncology at University Hospital in Kiel, Germany, provided an update on treatment of cutaneous squamous cell carcinoma during HemOnc Today Melanoma and Cutaneous Malignancies.

“Cutaneous squamous cell carcinoma is the second most frequent nonmelanoma skin cancer,” Hauschild said. “Ninety percent of these cases have an excellent prognosis because they carry good prognostic factors.”

The treatment of choice among physicians tends to be surgical excision. However, alternatives for inoperable and metastatic disease include radiotherapy, chemotherapy and EGFR inhibitors.

Reference:

Hauschild A. Update on advanced squamous cell carcinomas. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; March 24-25, 2017; New York.

Disclosure: Hauschild reports consultant or speakers roles with Amgen, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme, Novartis, OncoSec, Philogen, Peirre Fabre, Provectus, Regeneron and Roche.

    See more from HemOnc Today New York